By Mill Chart
Last update: Nov 14, 2023
Our stock screener has singled out ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) as a stellar value proposition. NASDAQ:RPRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. We'll explore this further.
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:RPRX scores a 8 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:RPRX scores a 6 out of 10:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:RPRX was assigned a score of 5 for health:
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:RPRX scores a 4 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of RPRX for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
ROYALTY PHARMA PLC- CL A
NASDAQ:RPRX (4/19/2024, 3:30:02 PM)
After market: 28.16 0 (0%)28.16
+0.27 (+0.97%)
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s...